Management of Advanced Prostate Cancer: Gonadotropin-Releasing Hormone Blockers Might Improve Prognosis
- 16 May 2008
- journal article
- editorial
- Published by Elsevier in European Urology
- Vol. 54 (4) , 726-727
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Degarelix: A Novel Gonadotropin-Releasing Hormone (GnRH) Receptor Blocker—Results from a 1-yr, Multicentre, Randomised, Phase 2 Dosage-Finding Study in the Treatment of Prostate CancerEuropean Urology, 2008
- EAU Guidelines on Prostate CancerEuropean Urology, 2008
- Redefining Clinically Significant Castration Levels in Patients With Prostate Cancer Receiving Continuous Androgen Deprivation TherapyJournal of Urology, 2007
- Failure to Maintain a Suppressed Level of Serum Testosterone during Long-Acting Depot Luteinizing Hormone-Releasing Hormone Agonist Therapy in Patients with Advanced Prostate CancerUrologia Internationalis, 2006
- Hormone Therapy in Prostate Cancer: LHRH Antagonists versus LHRH AnaloguesEuropean Urology, 2004
- Serum Testosterone Suppression and Potential for Agonistic Stimulation During Chronic Treatment With Monthly and 3-month Depot Formulations of Leuprolide Acetate for Advanced Prostate CancerJournal of Urology, 2002
- A Phase 3, Multicenter, Open Label, Randomized Study Of Abarelix Versus Leuprolide Plus Daily Antiandrogen In Men With Prostate CancerJournal of Urology, 2002
- THE GONADOTROPIN-RELEASING HORMONE ANTAGONIST ABARELIX DEPOT VERSUS LUTEINIZING HORMONE RELEASING HORMONE AGONISTS LEUPROLIDE OR GOSERELIN: INITIAL RESULTS OF ENDOCRINOLOGICAL AND BIOCHEMICAL EFFICACIES IN PATIENTS WITH PROSTATE CANCERJournal of Urology, 2001
- Reassessment of the definition of castrate levels of testosterone: implications for clinical decision makingUrology, 2000